Last reviewed · How we verify

Ombitasvir-Paritaprevir-Ritonavir — Competitive Intelligence Brief

Ombitasvir-Paritaprevir-Ritonavir (Ombitasvir-Paritaprevir-Ritonavir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV protease inhibitor and NS5A inhibitor combination. Area: Virology/Hepatology.

marketed HCV protease inhibitor and NS5A inhibitor combination HCV NS3/4A protease, HCV NS5A protein Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Ombitasvir-Paritaprevir-Ritonavir (Ombitasvir-Paritaprevir-Ritonavir) — University of Modena and Reggio Emilia. This combination inhibits hepatitis C virus NS3/4A protease, NS5A protein, and uses ritonavir as a pharmacokinetic booster to increase drug levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ombitasvir-Paritaprevir-Ritonavir TARGET Ombitasvir-Paritaprevir-Ritonavir University of Modena and Reggio Emilia marketed HCV protease inhibitor and NS5A inhibitor combination HCV NS3/4A protease, HCV NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV protease inhibitor and NS5A inhibitor combination class)

  1. University of Modena and Reggio Emilia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ombitasvir-Paritaprevir-Ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/ombitasvir-paritaprevir-ritonavir. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: